E A Strebkova
Research Subjects
E A Strebkova has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- A S Mashkov
Voronovskoye Moscow Clinical Center for Infectious Diseases
1 shared publication - A Y Karpunin
Regional Clinical Hospital
1 shared publication - A. S. Navasardyan
Samara regional clinical hospital named after V.D. Seredavin
1 shared publication - Anna Ivanovna Simakova
Pacific State Medical University
1 shared publication - B V Berezhanskiy
R-Pharm JSC
1 shared publication - Dzhamilya Yu. Kurmaeva
Penza State University
1 shared publication
Latest Publications
- Open Access
- 25 May 2021
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- Vol. 11 (2) , 5-10
Patients with CKD-5D and COVID infection. Individual organizational and clinical issues of therapy
New coronavirus infection (COVID-19) – a serious medical and social problem. Despite the achievement of certain successes in the treatment of patients with COVID-19, there is a need to develop special clinical and organizational approaches in patients with CKD who are on renal replacement therapy and are at special risk due to the course of the underlying disease and concomitant pathology. The article presents the experience of the Samara Regional Center of Nephrology and Dialysis of the Samara Regional Clinical Hospital named after V.D. Seredavin during the pandemic, as well as the features of the management of patients with stage 5 chronic kidney disease undergoing renal replacement therapy in the infectious department to provide MP to patients with COVID-19. Patients with CKD require increased attention, treatment of coronavirus infection (both specific and concomitant) should be carried out in full, while observing the regimens and dosage regimens of drugs and their combinations.
- 25 May 2021
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- Vol. 11 (2) , 5-10
Open AccessPatients with CKD-5D and COVID infection. Individual organizational and clinical issues of therapy
New coronavirus infection (COVID-19) – a serious medical and social problem. Despite the achievement of certain successes in the treatment of patients with COVID-19, there is a need to develop special clinical and organizational approaches in patients with CKD who are on renal replacement therapy and are at special risk due to the course of the underlying disease and concomitant pathology. The article presents the experience of the Samara Regional Center of Nephrology and Dialysis of the Samara Regional Clinical Hospital named after V.D. Seredavin during the pandemic, as well as the features of the management of patients with stage 5 chronic kidney disease undergoing renal replacement therapy in the infectious department to provide MP to patients with COVID-19. Patients with CKD require increased attention, treatment of coronavirus infection (both specific and concomitant) should be carried out in full, while observing the regimens and dosage regimens of drugs and their combinations.
- Open Access
- 15 December 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (12) , 148-154
Experience of olokizumab use in COVID-19 patients
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm. Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it. Aim.To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting. Materials and methods.The analysis included data of 610 subjects aged 55.0812.68 years who received olokizumab at a single dose of 160 mg/mL 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.2311.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome. Results.If a cytokine storm occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation. Conclusion.The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.
- 15 December 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (12) , 148-154
Open AccessExperience of olokizumab use in COVID-19 patients
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm. Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it. Aim.To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting. Materials and methods.The analysis included data of 610 subjects aged 55.0812.68 years who received olokizumab at a single dose of 160 mg/mL 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.2311.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome. Results.If a cytokine storm occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation. Conclusion.The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.